BioCentury | Feb 20, 2012
Strategy

Externalizing neurology

AstraZeneca plc is betting that significantly downsizing internal R&D in neurology will allow it to run cheaper and faster - and if necessary fail more quickly and cost-effectively - in a disease area that has historically high...
BC Week In Review | Apr 9, 2007
Company News

Hypnion, Eli Lilly deal

LLY completed its previously announced acquisition of Hypnion for $315 million in cash (see BioCentury, March 12, 2007). Hypnion Inc. , Lexington, Mass.   Eli Lilly and Co. (LLY), Indianapolis, Ind.   Business: Neurology  ...
BC Week In Review | Mar 12, 2007
Company News

Hypnion, Eli Lilly deal

LLY will acquire Hypnion for an undisclosed amount of cash. Hypnion's oral HY10275 is in Phase II testing to treat insomnia by improving both sleep induction and maintenance. In January, Phase II data showed the...
BioCentury | Mar 12, 2007
Finance

Ebb & Flow

Undaunted by the uncertainty following the market sell-off on Feb. 27, IPO hopefuls continue to make their way toward the market. Last week, Jazz announced plans to raise up to $172.5 million. A handful of...
BC Extra | Mar 6, 2007
Company News

Eli Lilly to acquire Hypnion

LLY will acquire neurology company Hypnion (Lexington, Mass.) for an undisclosed amount of cash. Hypnion's oral HY10275 is in Phase II testing to treat insomnia by improving both sleep induction and maintenance. In January, Phase...
BioCentury | Jan 15, 2007
Product Development

WASO comparisons

WASO comparisons WASO comparisons Comparing sleep maintenance outcomes for marketed drugs and competitors in development. (A) Decrease in wake time after onset of sleep in minutes vs. placebo Dose Patients Decrease in WASO (A) p-value...
BioCentury | Jan 15, 2007
Product Development

Staying asleep

Although the data will need to be confirmed in Phase III trials, Hypnion Inc. has disclosed Phase II results showing that HY10275 improved sleep maintenance, as measured by wake time after onset of sleep (WASO),...
BC Week In Review | Jan 8, 2007
Clinical News

HY10275: Phase II data

In a double-blind, placebo-controlled, French Phase II trial in 52 patients, 1 and 3 mg doses of oral HY10275 met the primary endpoint of significant improvement in WASO, a measure of sleep maintenance. Specifically, WASO...
BC Extra | Jan 6, 2007
Clinical News

Hypnion's HY10275 meets insomnia endpoint

Hypnion (Lexington, Mass.) said oral HY10275 met the primary endpoint of a reduction in wake after sleep onset (WASO) in a Phase II trial to treat insomnia. In the double-blind, French trial in 52 patients,...
BC Week In Review | Oct 30, 2006
Company News

CoLucid management update

CoLucid Pharmaceuticals Inc. , Indianapolis, Ind.   Business: Neurology   Hired: James White as president, CEO and a director, formerly COO and EVP of R&D at Hypnion Inc.; Nadia Rupniak as executive director of project and...
Items per page:
1 - 10 of 27
BioCentury | Feb 20, 2012
Strategy

Externalizing neurology

AstraZeneca plc is betting that significantly downsizing internal R&D in neurology will allow it to run cheaper and faster - and if necessary fail more quickly and cost-effectively - in a disease area that has historically high...
BC Week In Review | Apr 9, 2007
Company News

Hypnion, Eli Lilly deal

LLY completed its previously announced acquisition of Hypnion for $315 million in cash (see BioCentury, March 12, 2007). Hypnion Inc. , Lexington, Mass.   Eli Lilly and Co. (LLY), Indianapolis, Ind.   Business: Neurology  ...
BC Week In Review | Mar 12, 2007
Company News

Hypnion, Eli Lilly deal

LLY will acquire Hypnion for an undisclosed amount of cash. Hypnion's oral HY10275 is in Phase II testing to treat insomnia by improving both sleep induction and maintenance. In January, Phase II data showed the...
BioCentury | Mar 12, 2007
Finance

Ebb & Flow

Undaunted by the uncertainty following the market sell-off on Feb. 27, IPO hopefuls continue to make their way toward the market. Last week, Jazz announced plans to raise up to $172.5 million. A handful of...
BC Extra | Mar 6, 2007
Company News

Eli Lilly to acquire Hypnion

LLY will acquire neurology company Hypnion (Lexington, Mass.) for an undisclosed amount of cash. Hypnion's oral HY10275 is in Phase II testing to treat insomnia by improving both sleep induction and maintenance. In January, Phase...
BioCentury | Jan 15, 2007
Product Development

WASO comparisons

WASO comparisons WASO comparisons Comparing sleep maintenance outcomes for marketed drugs and competitors in development. (A) Decrease in wake time after onset of sleep in minutes vs. placebo Dose Patients Decrease in WASO (A) p-value...
BioCentury | Jan 15, 2007
Product Development

Staying asleep

Although the data will need to be confirmed in Phase III trials, Hypnion Inc. has disclosed Phase II results showing that HY10275 improved sleep maintenance, as measured by wake time after onset of sleep (WASO),...
BC Week In Review | Jan 8, 2007
Clinical News

HY10275: Phase II data

In a double-blind, placebo-controlled, French Phase II trial in 52 patients, 1 and 3 mg doses of oral HY10275 met the primary endpoint of significant improvement in WASO, a measure of sleep maintenance. Specifically, WASO...
BC Extra | Jan 6, 2007
Clinical News

Hypnion's HY10275 meets insomnia endpoint

Hypnion (Lexington, Mass.) said oral HY10275 met the primary endpoint of a reduction in wake after sleep onset (WASO) in a Phase II trial to treat insomnia. In the double-blind, French trial in 52 patients,...
BC Week In Review | Oct 30, 2006
Company News

CoLucid management update

CoLucid Pharmaceuticals Inc. , Indianapolis, Ind.   Business: Neurology   Hired: James White as president, CEO and a director, formerly COO and EVP of R&D at Hypnion Inc.; Nadia Rupniak as executive director of project and...
Items per page:
1 - 10 of 27